Caremark's "$8.5 billion" settlement is a projection. CVS pays nothing.
The FTC closed its insulin case against CVS's pharmacy benefit manager with conduct terms the company says it largely follows already.
The FTC settled with Caremark and its rebate aggregator, Zinc Health Services, on July 14, 2026. The complaint said Caremark made formulary placement depend on rebates, so list prices rose and patients with list-price cost-sharing absorbed the increase.
The order requires Caremark to stop disadvantaging lower-cost versions on standard formularies and pass rebates to members at the point of sale. An independent monitor oversees compliance for three years. The FTC says this locks in up to $8.5 billion in consumer savings over a decade, with up to $4.5 billion more from point-of-sale rebates.
Both numbers are the agency's estimates of what the remedies might save. The settlement includes no monetary penalty and contains carve-outs that may limit its reach in practice. CVS's own response was that many of the measures match what it already does. If that is right, the order changes little. If it is wrong, the conduct the FTC described ran for years and costs CVS nothing.
CVS carries other exposure: about $5 billion over 10 years in the state opioid settlements, a $948.8 million Omnicare judgment now in bankruptcy, and an open Justice Department opioid-dispensing case. None of it is collected here. Until fees actually change on live formularies, $8.5 billion is a press-release number.
Sources
- managedhealthcareexecutive.com · managedhealthcareexecutive.com/view/ftc-secures-settlement-with-caremark-locks-in-up-to-8-…
- goodwinlaw.com · goodwinlaw.com/en/insights/publications/2026/07/alerts-lifesciences-hltc-caremark-settles-…
Cite this report
The Precedent. "Caremark's "$8.5 billion" settlement is a projection. CVS pays nothing.." September 22, 2026. https://theprecedent.org/article/caremarks-85-billion-settlement-is-a-projection-cvs-pays-nothing
